Compare Fabrinet (FN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs GeneDx Holdings Corp — how do they compare? Fabrinet trades at $581.18 (market cap $18.84B), while GeneDx Holdings Corp trades at $82.19 (market cap $2.44B). The key difference: Fabrinet is far larger — about 7.7× GeneDx Holdings Corp's market cap, and Fabrinet is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| FN | WGS | |
|---|---|---|
Market Cap | $18.84B | $2.44B |
Sector | Technology | Technology |
52-Week High | $746.47 | $167.51 |
52-Week Low | $277.04 | $34.51 |
Enterprise Value | $17.90B | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $583.95, up 10.79% in 24 hours, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $3.81. Revenue grew to $3.42 billion in 2025, with a net income margin of 9.94%, while the company maintains a debt-free balance sheet and strategic positioning in AI optical supply chains.
Outlook is positive due to robust AI-driven demand and expansion plans, though risks include premium valuation (P/E 45.18) and supply chain constraints. Analysts are bullish with 75% buy ratings and a $661.75 price target (MarketBeat, 2026-07-07), but technical indicators suggest near-term resistance near $532.
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
